{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:11:37Z","timestamp":1773216697759,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"national health and medical research council","doi-asserted-by":"publisher","award":["1158722"],"award-info":[{"award-number":["1158722"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"telethon new children's hospital research fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The purpose of this double-blind, randomised, controlled trial is to compare allergic outcomes in children following vaccination with acellular pertussis (aP) antigen (standard of care in Australia) given at 2 months of age versus whole cell pertussis (wP) in the infant vaccine schedule.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Up to 3000 Australian infants 6 to &lt;12 weeks of age born \u226532 weeks gestation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>The intervention is a wP containing vaccine as the first scheduled pertussis vaccine dose instead of an aP containing vaccine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcomes<\/jats:title><jats:p>The primary outcome is a binary indicator of history of IgE-mediated food allergy at the age of 12 months confirmed, where necessary, with an oral food challenge before 18 months of age. Secondary outcomes include (1) history of parent-reported clinician-diagnosed new onset of atopic dermatitis by 6 or 12 months of age with a positive skin prick test to any allergen before 12 months of age, (2) geometric mean concentration in pertussis toxin-specific IgG before and 21 to 35 days after a booster dose of aP at 18 months of age, and (3) sensitisation to at least one allergen by 12 months of age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Operating characteristics of trial decision rules were evaluated by trial simulation. The selected rules for success and futility approximately maintain type I error of 0.05 and achieved power 0.85 for a reduction in the primary outcome from 10% in the control group to 7% in the intervention group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>A detailed, prospective statistical analysis plan (SAP) is presented for this Bayesian adaptive design. The plan was written by the trial statistician and details the study design, pre-specified adaptive elements, decision thresholds, statistical methods, and the simulations used to evaluate the operating characteristics of the trial. Application of this SAP will minimise bias and supports transparent and reproducible research.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>Australia &amp; New Zealand Clinical Trials Registry,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12617000065392\">ACTRN12617000065392<\/jats:ext-link>. Registered on 12 January 2017<\/jats:p><\/jats:sec><jats:sec><jats:title>Study protocol<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"https:\/\/doi.org\/10.1136\/bmjopen-2020-042838\">10.1136\/bmjopen-2020-042838<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1186\/s13063-021-05874-6","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T09:06:40Z","timestamp":1644224800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell\/acellular pertussis vaccine schedule"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9459-2566","authenticated-orcid":false,"given":"James A.","family":"Totterdell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladymar Perez","family":"Chacon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie J.","family":"Estcourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie A.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"issue":"6","key":"5874_CR1","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.jaip.2019.12.020","volume":"8","author":"MJ Estcourt","year":"2020","unstructured":"Estcourt MJ, Campbell DE, Gold MS, Richmond P, Allen KJ, Quinn HE, Marsh JA, Peters RL, Valerio C, Dai D, et al. Whole-cell pertussis vaccination and decreased risk of ige-mediated food allergy: A nested case-control study. J Allergy Clin Immunol Pract. 2020; 8(6):2004\u201314.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5874_CR2","doi-asserted-by":"crossref","unstructured":"Perez Chacon G, Estcourt MJ, Totterdell J, Campbell DE, Perrett KP, Marsh JA, Richmond PC, Wood N, Gold MS, Holt PG, Waddington CS, Snelling TL. OPTIMUM study protocol: an adaptive randomised controlled trial of a mixed whole-cell\/acellular pertussis vaccine schedule. BMJ Open. 2020; 10(12). https:\/\/doi.org\/10.1136\/bmjopen-2020-042838. http:\/\/arxiv.org\/abs\/https:\/\/bmjopen.bmj.com\/content\/10\/12\/e042838.full.pdf.","DOI":"10.1136\/bmjopen-2020-042838"},{"issue":"6","key":"5874_CR3","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.jaci.2012.10.017","volume":"130","author":"HA Sampson","year":"2012","unstructured":"Sampson HA, Van Wijk RG, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, Dubois AE, Beyer K, Eigenmann PA, Spergel JM, et al. Standardizing double-blind, placebo-controlled oral food challenges: American academy of allergy, asthma & immunology\u2013european academy of allergy and clinical immunology practall consensus report. J Allergy Clin Immunol. 2012; 130(6):1260\u201374.","journal-title":"J Allergy Clin Immunol"},{"issue":"1-2","key":"5874_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jim.2008.02.018","volume":"335","author":"PG van Gageldonk","year":"2008","unstructured":"van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to bordetella pertussis, diphtheria and tetanus. J Immunol Methods. 2008; 335(1-2):79\u201389.","journal-title":"J Immunol Methods"},{"key":"5874_CR5","doi-asserted-by":"publisher","first-page":"101360","DOI":"10.1016\/j.mex.2021.101360","volume":"8","author":"SM McAlister","year":"2021","unstructured":"McAlister SM, van den Biggelaar AHJ, Thornton RB, Richmond PC. Optimising a 6-plex tetanus-diphtheria-pertussis fluorescent bead-based immunoassay. MethodsX. 2021; 8:101360. https:\/\/doi.org\/10.1016\/j.mex.2021.101360.","journal-title":"MethodsX"},{"key":"5874_CR6","unstructured":"World Health Organization. Immunological basis for immunization series: Module 3: Tetanus [online]. Geneva; 2018. Available: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/275340\/9789241513616-eng.pdf?ua=1. Accessed 17 Nov 2021."},{"issue":"6","key":"5874_CR7","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","volume":"147","author":"R K\u00e4yhty","year":"1983","unstructured":"K\u00e4yhty R, Peltola H, Karanko V, M\u00e4kel\u00e4 PH. The protective level of serum antibodies to the capsular polysaccharide of haemophilus influenzae type b. J Infect Dis. 1983; 147(6):1100.","journal-title":"J Infect Dis"},{"issue":"19","key":"5874_CR8","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","volume":"25","author":"GR Siber","year":"2007","unstructured":"Siber GR, Chang I, Baker S, Fernsten P, O\u2019Brien KL, Santosham M, Klugman KP, Madhi SA, Paradiso P, Kohberger R. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007; 25(19):3816\u201326.","journal-title":"Vaccine"},{"key":"5874_CR9","unstructured":"World Health Organization. Biologicals [Online]. Recommendations for the production & control of pneumococcal conjugate vaccines. 2002. Available: https:\/\/www.who.int\/biologicals\/publications\/en\/pneumococcal_conjugate_raccines_recomm_nov_2003.pdf. Accessed: 8 Jul 2020."},{"issue":"20","key":"5874_CR10","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1016\/j.vaccine.2012.01.086","volume":"30","author":"VJ Menon","year":"2012","unstructured":"Menon VJ, Corscadden KJ, Fuery A, Thornton RB, Kirkham L-AS, Richmond PC, Wiertsema SP. Children with otitis media mount a pneumococcal serotype specific serum igg and iga response comparable to healthy controls after pneumococcal conjugate vaccination. Vaccine. 2012; 30(20):3136\u201344.","journal-title":"Vaccine"},{"issue":"5-6","key":"5874_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.vaccine.2003.09.007","volume":"22","author":"SM Marcy","year":"2004","unstructured":"Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Jones MC, Hansen J, Labadie J, Lee L, Martin BL, O\u2019Brien K, Rothstein E, Vermeer P. Fever as an adverse event following immunization: Case definition and guidelines of data collection, analysis, and presentation. Vaccine. 2004; 22(5-6):551\u20136. https:\/\/doi.org\/10.1016\/j.vaccine.2003.09.007.","journal-title":"Vaccine"},{"issue":"5","key":"5874_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.vaccine.2010.11.065","volume":"29","author":"J Gidudu","year":"2011","unstructured":"Gidudu J, Sack DA, Pina M, Hudson MJ, Kohl KS, Bishop P, Chatterjee A, Chiappini E, Compingbutra A, da Costa C, Fernandopulle R, Fischer TK, Haber P, Masana W, de Menezes MR, Kang G, Khuri-Bulos N, Killion LA, Nair C, Poerschke G, Rath B, Salazar-Lindo E, Setse R, Wenger P, Wong VCN, Zaman K. Diarrhea: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011; 29(5):1053\u201371. https:\/\/doi.org\/10.1016\/j.vaccine.2010.11.065.","journal-title":"Vaccine"},{"issue":"52","key":"5874_CR13","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.1016\/j.vaccine.2008.10.006","volume":"26","author":"J Gidudu","year":"2008","unstructured":"Gidudu J, Kohl KS, Halperin S, Hammer SJ, Heath PT, Hennig R, Hoet B, Rothstein E, Schuind A, Varricchio F, Walop W. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2008; 26(52):6800\u201313. https:\/\/doi.org\/10.1016\/j.vaccine.2008.10.006.","journal-title":"Vaccine"},{"issue":"31","key":"5874_CR14","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1016\/j.vaccine.2007.04.056","volume":"25","author":"KS Kohl","year":"2007","unstructured":"Kohl KS, Walop W, Gidudu J, Ball L, Halperin S, Hammer SJ, Heath P, Varricchio F, Rothstein E, Schuind A, Hennig R. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine. 2007; 25(31):5858\u201374. https:\/\/doi.org\/10.1016\/j.vaccine.2007.04.056.","journal-title":"Vaccine"},{"issue":"31","key":"5874_CR15","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1016\/j.vaccine.2007.04.062","volume":"25","author":"KS Kohl","year":"2007","unstructured":"Kohl KS, Walop W, Gidudu J, Ball L, Halperin S, Hammer SJ, Heath P, Hennig R, Rothstein E, Schuind A, Varricchio F. Induration at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2007; 25(31):5839\u201357. https:\/\/doi.org\/10.1016\/j.vaccine.2007.04.062.","journal-title":"Vaccine"},{"key":"5874_CR16","volume-title":"Bayesian approaches to clinical trials and health-care evaluation","author":"DJ Spiegelhalter","year":"2004","unstructured":"Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. London: Wiley; 2004."},{"key":"5874_CR17","doi-asserted-by":"publisher","DOI":"10.1201\/EBK1439825488","volume-title":"Bayesian adaptive methods for clinical trials","author":"SM Berry","year":"2010","unstructured":"Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian adaptive methods for clinical trials. New York: CRC press; 2010."},{"key":"5874_CR18","unstructured":"World Health Organization. Annex 9 - Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO technical report series 1004: World Health Organization; 2017. https:\/\/www.who.int\/publications\/m\/item\/WHO-TRS-1004-web-annex-9. Accessed 12 Nov 2021."},{"key":"5874_CR19","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021. R Foundation for Statistical Computing. https:\/\/www.R-project.org\/. Accessed 22 July 2021."},{"key":"5874_CR20","unstructured":"Stan Development Team. Stan Modeling Language Users Guide and Reference Manual. 2021. https:\/\/mc-stan.org. Accessed 22 July 2021."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05874-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T03:59:07Z","timestamp":1674705547000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05874-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5874"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05874-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"22 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval has been granted by the Child and Adolescent Health Service Human Research Ethics Committee, Perth, Western Australia (RGS 00019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}